Schisandra
Schisandra chinensis · Wu Wei Zi · The Five-Flavor Berry
Evidence grade 2 of 5, Thin. Read how the Atlas grades evidence.
The honest headline is that most of what is known about schisandra comes from animals and test tubes, not from people. The single largest recent liver dataset, a 2025 systematic review and preclinical meta-analysis in Frontiers in Pharmacology, pooled 54 animal studies covering 1,314 rats and mice and found large reductions in the liver enzymes ALT and AST and in the oxidative marker MDA, alongside higher SOD and glutathione, all at p<0.001. Not one of those 54 studies was human, none reported blinding or allocation concealment, and heterogeneity was high, so the authors themselves call for clinical trials to confirm the signal. Memorial Sloan Kettering's monograph is blunt that only a small number of human studies exist and that they are too limited to draw conclusions, with the more promising human data coming from combination formulas rather than schisandra alone. The best-characterized human effect is a drug interaction rather than a benefit: in 12 healthy volunteers, a Schisandra sphenanthera extract raised tacrolimus AUC by about 164 percent and Cmax by about 227 percent. That places the honest grade at preliminary/observational, a 2, higher than pure tradition because of consistent mechanistic and animal data but well short of the 3 the entry currently carries, since human efficacy trials on schisandra by itself remain thin.
- FDA
- Legal supplement (DSHEA)
- WADA
- Not prohibited
Reference only. Not medical advice.
What can go wrong
Generally well tolerated at studied doses, but meaningful CYP3A4 and P-glycoprotein drug interactions (documented with tacrolimus) and thin human safety data make clinician review essential for anyone on medication or pregnant.
Schisandra chinensis is the five-flavor berry of traditional Chinese medicine, Wu Wei Zi, so named because a single fruit is said to carry sweet, sour, bitter, salty and pungent notes at once. Its activity is credited to a family of dibenzocyclooctadiene lignans, among them schisandrin A, B and C and the gomisins, which act on liver enzymes and antioxidant defenses. The most studied use is liver protection, but that case rests almost entirely on animal and cell work rather than human trials. In people, the clearest and best-documented effect is actually a drug interaction, since schisandra can meaningfully change how the body handles medicines cleared by CYP3A4. The endurance, cognitive and anti-fatigue claims trace to twentieth-century Soviet adaptogen research and remain preliminary, often tested inside combination formulas rather than as schisandra alone.
The five-flavor berry with parallel Chinese hepatic and Soviet performance research traditions.
What people take it for
These are the reasons people give for taking it. They are not effects it has been shown to have.
How it is supposed to work
Schisandra chinensis is a deciduous climbing vine native to Northeast China, the Russian Far East (Primorsky Krai, Khabarovsk Krai), Korea, and Japan. Its bright red berries, called Wu Wei Zi (五味子, "five-flavor fruit") in Chinese traditional medicine, combine sweet, sour, bitter, salty, and pungent tastes in a single fruit, an unusual organoleptic profile that gives the plant its name. The traditional positioning in TCM emphasizes liver and kidney support, mental clarity, and "stabilizing" qualities that map approximately to modern stress-adaptation and metabolic support framings. Beyond Chinese tradition, Schisandra has a substantial parallel research heritage in Soviet aviation, cosmonaut, and military performance programs through the Brekhman era (1960s-80s), making it one of the few traditional medicines with substantial documentation in both Chinese clinical and Russian experimental research traditions. The active compound profile centers on a class of dibenzocyclooctadiene lignans unique to the Schisandra genus. Schisandrin A, schisandrin B, and schisandrin C are the foundational characterized compounds; gomisin A, gomisin N, and related gomisins extend the active compound family. These lignans accumulate in the berries (less in stems and leaves) and provide the basis for modern standardization. The dominant clinical evidence base is in hepatic protection, schisandrin and gomisin compounds support hepatic glutathione synthesis, modulate cytochrome P450 enzymes (particularly inducing CYP3A4 with relevant drug interaction implications), provide antioxidant protection in hepatic mitochondria, and produce anti-inflammatory effects in hepatic tissue. Chinese clinical research has used Schisandra and schisandrin compounds in hepatitis (particularly chronic hepatitis B and drug-induced hepatitis) for decades, with substantial published evidence in Chinese journals. The CYP450 modulation produces clinically meaningful drug interactions, schisandrin B is a CYP3A4 inducer that can reduce plasma concentrations of statins, calcium channel blockers, immunosuppressants (tacrolimus, cyclosporine), and other CYP3A4 substrates. The Soviet performance research focused on physical endurance, mental performance under stress, and "stabilizing" effects in high-stress occupational contexts, building substantial evidence base for adaptogenic positioning. The two-track evidence base (Chinese hepatic clinical + Soviet performance experimental) makes Schisandra unusual in adaptogen pharmacology.
How it is taken
Standard modern Schisandra dosing for hepatic and adaptogenic applications follows the 500-1500mg/day standardized extract paradigm (with variable schisandrin content standardization across products). The Park 2009 and 2014 hepatic protection trials used Schisandra extract for 12-week protocols. For traditional TCM preparation, 2-9g of dried berries daily in decoction (water-boiled extraction) is the classical range, typically combined in multi-herb formulas rather than monotherapy. The Russian tincture tradition uses 20-30 drops 2-3 times daily of concentrated alcoholic tincture. Take with or without food; absorption is acceptable either way. Effects on hepatic enzymes develop over 8-12 weeks of consistent use; adaptogenic and stress effects develop similarly over weeks. The CRITICAL dosing principle for Schisandra users is the CYP450 drug interaction concern, schisandrin B is a CYP3A4 inducer with clinically meaningful implications for users on CYP3A4 substrate medications. Statins, calcium channel blockers, immunosuppressants (particularly tacrolimus and cyclosporine in transplant patients), oral contraceptives, antiviral medications, and many other commonly prescribed drugs are CYP3A4 substrates that can be affected. Prescribing physician coordination is essential for users on chronic medications. The pregnancy contraindication is established in TCM tradition and modern guidance. Quality matters substantially, species substitution (S. chinensis vs S. sphenanthera) and standardization variability produce inconsistent clinical outcomes. Verify S. chinensis species specification and schisandrin standardization for clinical-grade use.
- Standardized extract
- 500-1500mg/day for 12+ weeks
- Traditional dried berry
- 2-9g/day in decoction
- Russian tincture
- 20-30 drops 2-3 times daily
- Standardization marker
- Schisandrins (variable %)
- Time to hepatic effect
- 8-12 weeks
- Time to adaptogenic effect
- 2-6 weeks
- CYP3A4 interaction
- Significant clinical consideration
- Pregnancy
- CONTRAINDICATED
Which form to buy
Not all preparations of the same ingredient are the same thing, and the trials were run on particular ones.
Schisandra Standardized Extract (1-9% Schisandrins)
Standardized extract typically targeting 1-9% schisandrins (varies across manufacturers and target indications). Used in most modern Western clinical trials including Hancke 1996, Park 2009, Park 2014. Standardization parameters vary across products; verify schisandrin content for therapeutic use. Brands include Pure Encapsulations, Designs for Health, Gaia Herbs, Thorne, and others.
Whole Dried Berry (Traditional TCM)
Whole dried berries used in classical TCM preparations and modern Chinese clinical practice. Traditional decoction (boiled water extraction) is the foundational preparation. Quality varies based on harvest, drying, and storage. Active compound content lower than concentrated extracts but full plant compound matrix preserved.
Schisandra Tincture / Liquid Extract
Alcoholic tinctures (typically 1:3-1:5 ratio) used in Russian traditional medicine and modern herbal practice. Flexible dosing; rapid absorption. Russian tradition typically uses concentrated tincture (40-50% alcohol).
ADAPT-232 (Schisandra + Eleutherococcus + Rhodiola)
Branded adaptogen combination from Swedish Herbal Institute used in Aslanyan 2010 cognitive trial and other clinical research. Reasonable evidence base for combined adaptogen approach. Premium pricing reflects clinical-trial inheritance.
Bicyclol (Schisandrin C Synthetic Analog)
Synthetic analog of schisandrin C developed in China and marketed as pharmaceutical hepatoprotectant for chronic hepatitis and drug-induced liver injury. Prescription product in China; substantial clinical evidence base. Not a consumer supplement; pharmaceutical context only.
TCM Multi-Herb Formulas with Schisandra
Schisandra appears in numerous classical TCM formulas including Sheng Mai San (with American ginseng and ophiopogon), and various tonification preparations. Traditional formulas typically use Schisandra as supporting herb rather than primary; therapeutic Schisandra dose may not be achieved in some commercial multi-herb products.
Schisandra Berry Powder
Whole-berry powder for blending into drinks, food, or capsules. Quality and active compound content varies; cost-effective option for users wanting whole-plant compound matrix. Distinctive five-flavor profile noticeable in unblended powder.
S. sphenanthera (Southern Schisandra) Substitution
S. sphenanthera is a different species (Nan Wu Wei Zi, "Southern Schisandra") with distinct lignan profile (more deoxyschisandrin, less schisandrin C). Sometimes commercially substituted for S. chinensis without consumer awareness. Different pharmacology; not interchangeable. Verify S. chinensis specification.
Who it works for, and who it does not
Liver function support and hepatic protection
The strongest clinical indication. Park 2009 and 2014 Korean trials support modest reductions in elevated liver enzymes (ALT, AST) in users with subclinical hepatic stress. Lebedev 2001 supports similar Russian evidence. Mechanistically grounded (hepatic glutathione, CYP450 modulation, antioxidant). Reasonable component of comprehensive liver support protocols.
Chronic hepatitis (adjunctive, particularly Chinese clinical inheritance)
Substantial Chinese clinical inheritance using Schisandra (and isolated schisandrin compounds) in chronic hepatitis B and other hepatic conditions. Bicyclol (synthetic schisandrin C analog) is prescription hepatoprotectant in China. Western evidence base for hepatitis adjunctive use is thinner; hepatology coordination essential.
Athletic and physical performance
Hancke 1996 and Soviet research tradition support modest endurance and recovery benefits. Effect sizes smaller than caffeine or established sport supplements. Reasonable component of comprehensive sport nutrition for users in stress-heavy training contexts.
Mental performance under stress
Aslanyan 2010 (ADAPT-232 combination) supports cognitive performance improvements under stress conditions. Soviet research tradition supports mental endurance applications. Reasonable component of nootropic protocols, particularly in adaptogen combinations.
Stress and fatigue (adaptogenic)
Soviet adaptogen research tradition supports stress and fatigue applications. Modern Western evidence is thinner than for Rhodiola or Ashwagandha in this specific indication. Reasonable component of comprehensive stress nutrition protocols.
Drug-induced liver injury risk
Theoretical hepatoprotective role in users on hepatotoxic medications. Chinese pharmaceutical Bicyclol used in this context. Western clinical evidence limited; coordinate with treating physician, note the CYP450 induction concern that may reduce concurrent drug efficacy.
Users on CYP3A4 substrate medications
CRITICAL CYP450 interaction concern. Schisandrin B is a CYP3A4 inducer that can substantially reduce plasma concentrations of statins, calcium channel blockers, immunosuppressants (tacrolimus, cyclosporine), warfarin (variable effects), oral contraceptives, antiviral medications, and many other CYP3A4 substrates. Coordinate with prescribing physicians for any concurrent medication use.
Pregnancy and lactation
TCM traditional contraindication (Schisandra is traditionally avoided in pregnancy in classical Chinese medicine). Limited modern safety data. Generally avoid during pregnancy and lactation.
Active peptic ulcer or severe GERD
Schisandra has acidifying effects and can exacerbate peptic ulcer or severe gastroesophageal reflux. Caution in users with these conditions; coordinate with gastroenterology if pursuing.
Taken with other things
Combinations people actually use. Evidence for one ingredient is not evidence for a pair.
Milk Thistle (Silymarin)
Common hepatoprotective combination. Mechanistically complementary, Schisandra modulates CYP450 and hepatic glutathione; milk thistle provides direct hepatocyte membrane stabilization. Reasonable comprehensive liver support combination.
NAC (N-acetylcysteine)
Mechanistically complementary for hepatic glutathione support. NAC provides cysteine substrate for glutathione synthesis; Schisandra supports glutathione utilization. Reasonable comprehensive liver protection combination.
Rhodiola and Eleutherococcus
Traditional Soviet adaptogen combination (basis of ADAPT-232 used in Aslanyan 2010). Mechanistically complementary adaptogen pharmacology. Common in modern adaptogen blends.
CYP3A4 Substrate Medications (Statins, Calcium Channel Blockers, Immunosuppressants)
CRITICAL INTERACTION. Schisandrin B is a CYP3A4 inducer that can substantially reduce plasma concentrations of these medications. Avoid combination or coordinate carefully with prescribing physician for dose adjustments and monitoring.
Tacrolimus and Cyclosporine (Transplant Immunosuppressants)
CRITICAL TRANSPLANT INTERACTION. Schisandra has been shown to substantially affect tacrolimus and cyclosporine concentrations in transplant patients, paradoxically sometimes INCREASING tacrolimus AUC (different from pure CYP3A4 induction prediction) in published case reports. Transplant patients should NOT use Schisandra without transplant medicine coordination.
Warfarin
Variable effects on warfarin pharmacology reported in case reports. INR monitoring essential when initiating Schisandra in warfarin users; coordinate with prescribing physician.
Oral Contraceptives
Theoretical CYP3A4 induction may reduce oral contraceptive effectiveness. Limited specific case reports but mechanistically plausible. Consider backup contraception method or coordinate with prescribing physician.
Antiviral Medications (HIV, Hepatitis)
Many antiviral medications are CYP3A4 substrates. Theoretical and case-report reduction of antiviral concentrations. Coordinate with infectious disease/hepatology.
Pregnancy
TCM traditional contraindication. Limited modern safety data. Avoid during pregnancy and lactation.
What to look for on the label
Look for: explicit "Schisandra chinensis" species specification (NOT just "Schisandra"); schisandrin standardization (1-9% range, verify content); USP or NSF third-party verification; certified organic source if available given Asian agricultural quality control variability; reasonable price (premium for verified standardized extracts justified; very high pricing without specific quality differentiation suspect); clear dose disclosure. Avoid: products labeled simply "Schisandra" without species specification; products without standardization disclosure; products marketed for pregnancy use; transplant patients should avoid entirely without specialist coordination; products from manufacturers without third-party testing.
Safety in detail
- Generally well-tolerated at studied doses (500-1500mg/day standardized extract) in users without specific contraindications. No documented serious adverse events at standard supplementation doses in healthy users.
- CRITICAL CYP450 DRUG INTERACTION concern is the dominant safety consideration. CYP3A4 induction by schisandrin B affects numerous commonly prescribed medications. Prescribing physician coordination essential for users on chronic medications.
- Pregnancy contraindication established in TCM tradition and modern guidance.
- Active peptic ulcer or severe GERD caution due to acidifying effects.
- Mild GI upset (nausea, abdominal discomfort) at higher doses; managed by dividing dose or taking with food.
- Hepatotoxicity has been reported in rare cases, paradoxical given the hepatoprotective positioning. Monitor liver enzymes if symptoms develop during use.
- Mild stimulant effects can disrupt sleep at higher doses; take earlier in the day in sensitive users.
- Rash and allergic reactions reported in rare cases.
- Pediatric use: limited systematic safety data; not standard practice.
- Long-term safety record in TCM tradition is substantial; modern clinical trials confirm acceptable safety at studied doses with the noted drug interaction caveats.
What people get wrong
Often saidSchisandra is safe to combine with any prescription medication.
ActuallyIt is NOT. Schisandra has clinically meaningful CYP3A4 drug interactions affecting statins, calcium channel blockers, immunosuppressants, oral contraceptives, antivirals, and many other commonly prescribed medications. Prescribing physician coordination is essential.
Often saidAll Schisandra species are interchangeable.
ActuallyS. chinensis (Northern, Wu Wei Zi) and S. sphenanthera (Southern, Nan Wu Wei Zi) are different species with distinct lignan profiles. Most modern clinical evidence is for S. chinensis specifically. Species verification matters for therapeutic use.
Often saidSchisandra cures liver disease.
ActuallyModest hepatic protection effects in subclinical hepatic stress are supported by modern evidence. Effect sizes are smaller than pharmaceutical hepatoprotectants. Reasonable component of comprehensive liver support; not substitute for established hepatology care in serious liver disease.
Often saidSchisandra is safe for transplant patients on immunosuppressants.
ActuallyIt is NOT. Schisandra-tacrolimus interactions have been documented in published case reports and can substantially affect immunosuppressant concentrations with serious clinical consequences. Transplant patients should avoid Schisandra without transplant medicine coordination.
Often saidHigher Schisandra doses always produce better results.
ActuallyMost clinical evidence clusters at 500-1500mg/day standardized extract. Higher doses produce diminishing returns and increased drug interaction concerns. The therapeutic window is real.
Often saidSoviet performance research means Schisandra is a powerful stimulant like caffeine.
ActuallyThe Soviet research supports modest endurance and mental performance benefits, not caffeine-equivalent stimulation. Realistic effect-size expectations matter.
Often saidPregnancy use is safe because Schisandra is a traditional herb.
ActuallyTCM tradition contraindicates Schisandra in pregnancy. Modern guidance follows. The "traditional means safe in pregnancy" framing is incorrect for Schisandra.
Who profits, and who pushes back
Mainstream pharmacology
The CYP3A4 induction by Schisandra is a clinically meaningful drug interaction that affects numerous commonly prescribed medications (statins, calcium channel blockers, immunosuppressants, oral contraceptives, antivirals). Consumer Schisandra marketing often inadequately addresses these interactions. Mainstream pharmacology and herb-drug interaction databases consistently flag Schisandra as a CYP3A4 modulator requiring prescribing physician coordination. For transplant patients specifically, Schisandra-tacrolimus interactions can be substantially serious and warrant strong avoidance without transplant medicine coordination.
Conservative Western evidence assessment
The substantial Soviet (1960s-80s Brekhman era) and Chinese clinical research inheritance includes methodologically variable studies that may not meet modern Western RCT standards. The modern Western evidence base (Hancke 1996 forward) is more methodologically rigorous but still relatively limited compared to mainstream pharmaceuticals. The "centuries of TCM use + Soviet research + Chinese pharmaceutical + modern Western trials" framing should engage with the actual evidence quality at each stratum.
Alexander Panossian
Sells this. Has a commercial interest in a product sold as this compound, as of July 2026.
Comprehensive 2008 Schisandra adaptogen review and continued research. Substantial industry collaboration through Swedish Herbal Institute (ADAPT-232 manufacturer). Disclosed industry source.
Israel Brekhman
Foundational Soviet adaptogen researcher whose work in 1960s-80s built substantial Russian-language Schisandra evidence base for physical and mental performance applications. Independent academic; deceased.
Chinese hepatology and TCM community
Long-standing Chinese clinical use of Schisandra and isolated schisandrin compounds in chronic hepatitis and drug-induced liver injury. Substantial evidence base; Bicyclol prescription product reflects pharmacological development.
Swedish Herbal Institute
Sells this. Has a commercial interest in a product sold as this compound, as of July 2026.
Manufacturer of ADAPT-232 (Schisandra + Eleutherococcus + Rhodiola) clinical-trial form used in Aslanyan 2010. Substantial commercial interest; disclosed industry source.
Russian Far East indigenous medical knowledge
Long traditional use by Nanai, Udege, and other indigenous peoples for stamina during hunting and expeditions. Foundational traditional knowledge that informed Russian and Soviet scientific research.
Functional medicine community
Substantial functional medicine use for liver support, adaptogenic stress applications, and integration in adaptogen combinations. Diverse practice patterns; drug interaction awareness varies.
Where the research comes from
| Place | Share of published research |
|---|---|
| China | 42% |
| Russia | 22% |
| Korea | 16% |
| North America | 12% |
| Other | 8% |
Research published from: China · Russia.
How we got here
Schisandra's use in human medicine spans Chinese tradition (>2000 years documented), Korean traditional medicine, Russian Far East indigenous practice (Nanai, Udege peoples), and Japanese traditional medicine. The plant's inclusion in the Shennong Bencao Jing (Divine Farmer's Materia Medica, ~200 CE) as an "upper-class" (superior) herb established its position in Chinese medical tradition as a longevity and tonification agent. Wu Wei Zi ("five-flavor fruit") name reflects the unusual organoleptic profile that combines all five Chinese taste categories in a single berry, a feature that gives the plant cultural and medical distinctiveness. The Russian Far East tradition developed in parallel, indigenous peoples used Schisandra berries for stamina during long hunts and expeditions, and Russian expeditions to the Far East in the 19th century brought knowledge of the plant back to broader Russian culture. The 20th century Soviet scientific era integrated Schisandra into the adaptogen research program. Israel Brekhman's 1960s-80s research program included substantial Schisandra studies on physical and mental performance, with applications to military, athletic, and cosmonaut performance research. Russian "Adaptogen" pharmaceuticals incorporated Schisandra alongside Eleutherococcus and Rhodiola. The Chinese pharmaceutical era developed through the 1970s-90s with clinical research on Schisandra in chronic hepatitis B (endemic in China) and drug-induced liver injury. The development of Bicyclol, a synthetic analog of schisandrin C, as prescription pharmaceutical hepatoprotectant established the strongest pharmacological foundation for the hepatic protection indication. Bicyclol remains widely prescribed in China for chronic hepatitis and drug-induced liver injury. The modern Western clinical era developed through the 1990s-2010s. Hancke 1996 Chilean athletic trial provided early modern Western evidence. The Park 2009 and 2014 Korean trials established the modern hepatic protection clinical evidence. Aslanyan 2010 established cognitive performance evidence in adaptogen combinations. Alexander Panossian's 2008 comprehensive review (Phytomedicine) consolidated the integrated framework. The CYP450 drug interaction concern emerged through pharmacological research in the 2000s. The clinical implications for users on common medications (statins, calcium channel blockers, immunosuppressants) have become increasingly recognized in functional medicine and herb-drug interaction databases, but consumer awareness remains limited. The transplant immunosuppressant interaction is particularly serious and has been addressed in transplant medicine guidance. The consumer market has grown modestly through the 2010s-2020s. Schisandra has remained a smaller commercial category than ashwagandha or rhodiola despite substantial evidence base, partly reflecting the more complex pharmacology, the drug interaction concerns that limit broad consumer applicability, and the less accessible cultural framing for Western markets. The Soviet performance research heritage and Chinese hepatic clinical inheritance are particularly difficult to translate into typical consumer marketing.
- ~200 CEShennong Bencao Jing classification as superior tonification herb
- Centuries continuingChinese, Korean, Japanese, Russian Far East traditional use
- 1960s-80sSoviet Brekhman adaptogen research program substantial Schisandra studies
- 1970s-90sChinese clinical research on hepatitis and drug-induced liver injury
- 1980s-90sBicyclol (synthetic schisandrin C analog) developed as Chinese pharmaceutical
- 1996Hancke Chilean athletic performance trial
- 2001Lebedev Russian hepatic protection trial
- 2008Panossian comprehensive adaptogen review
- 2009Park Korean hepatic protection RCT
- 2010Aslanyan ADAPT-232 cognitive performance trial
- 2014Park subclinical liver damage RCT
- 2017Szopa comprehensive Polish review
- 2020sIncreasing consumer awareness of CYP450 drug interaction concerns
What we do not know
- Whether modern Western clinical evidence will catch up to the substantial Chinese clinical inheritance and Russian experimental research traditions in rigor and methodology.
- Optimal standardization parameters, current schisandrin standardization is convention but optimization research is limited; multiple lignan markers may better predict clinical outcomes.
- Whether S. chinensis and S. sphenanthera produce clinically distinguishable outcomes, different lignan profiles suggest different pharmacology but comparative clinical evidence is limited.
- How best to communicate the CYP450 drug interaction concern to consumers, current consumer guidance often inadequately addresses this clinically meaningful interaction.
- Whether the Chinese pharmaceutical Bicyclol provides clinical evidence that translates to Schisandra extract supplementation in Western practice.
- Whether Schisandra has applications in chronic fatigue syndrome, fibromyalgia, or post-viral fatigue conditions beyond the established adaptogenic positioning.
- How to address the transplant immunosuppressant interaction, substantially serious for transplant patients but not well-known outside specialist transplant medicine.
- Whether emerging cancer adjunct research (Schisandra in chemotherapy support) will produce clinical applications or remain preliminary.
Legal status
Universally available globally as dietary supplement. Legal under DSHEA in the United States and equivalent supplement regulations in most jurisdictions. Not on WADA prohibited list. Pharmaceutical Bicyclol (synthetic schisandrin C analog) is prescription-only in China and select Asian markets, not available as Western pharmaceutical. Major retail brands include Gaia Herbs, Pure Encapsulations, Designs for Health, Thorne, Solgar, Now Foods, and TCM-positioned brands. Russian and Eastern European markets have substantial traditional commerce in tinctures and dried berries alongside Western standardized products. Production is concentrated in China (Northeast provinces, particularly Heilongjiang), Russian Far East, and Korea. Sustainability concern: wild-harvest from Russian Far East has produced some overharvesting concerns; cultivated supply is expanding in China and Korea. Quality verification challenges include species substitution (S. chinensis vs S. sphenanthera) and standardization variability across commercial products.
Status current as of July 2026. Regulatory positions change, sometimes quickly.
The market for this
What follows describes how this is bought and sold. It is not a buying guide and it is not an endorsement of any seller.
Schisandra chinensis production is concentrated in Northeast China (particularly Heilongjiang and Jilin provinces), Russian Far East (Primorsky Krai, Khabarovsk Krai), Korea, and Japan. Wild-harvest from Russian Far East has been the historical primary source; sustainability concerns have driven expansion of cultivated supply in China. Quality verification challenges include species substitution (S. chinensis vs S. sphenanthera, different species with different lignan profiles), standardization variability (schisandrin content varies enormously based on plant variety, harvest, and processing), and pesticide/heavy metal contamination in some commercial sources. The American Botanical Council Botanical Adulterants Prevention Program has addressed species verification in adaptogen products including Schisandra. Third-party testing (HPTLC, DNA barcoding for species identity, HPLC for schisandrin quantification) provides quality verification for clinical-grade use. NSF and USP testing programs include Schisandra products.
At a glance
- Species
- Schisandra chinensis (Northern; clinical species)
- Chinese name
- Wu Wei Zi (五味子, "five-flavor fruit")
- Active compounds
- Schisandrins A/B/C, gomisins A/N
- Standardization marker
- Schisandrins (1-9% range)
- Strongest evidence
- Hepatic protection
- Foundational classical text
- Shennong Bencao Jing (~200 CE)
What this entry does not yet cover
What follows is unfinished work on our side, not a finding about Schisandra. A short entry is not a safe entry.
- Cost and market. We have not documented what it sells for or who sells it.
- Supply chain. We have not mapped where it is made.
- Who uses it. We have not documented the user groups.
- What could change. No forward-looking summary yet.
- How it compares. We have not set it against the alternatives.
- Children and teenagers. We have not checked what is known about younger people.
- Where we land. We have not taken a position on this yet.
Sources
2025 systematic review and preclinical meta-analysis of schisandra in liver injury pooled 54 animal studies and 1,314 animals with no human trials, showing large ALT, AST and MDA reductions and higher SOD and GSH at p<0.001, and calling for clinical trials.
In 12 healthy volunteers, Schisandra sphenanthera extract increased tacrolimus AUC by about 164 percent and Cmax by about 227 percent, attributed to CYP3A4 and P-glycoprotein inhibition, with gomisin C acting as a mechanism-based irreversible CYP3A4 inhibitor; blood levels must be monitored.
Only a small number of human studies exist and they are too limited to draw conclusions; no serious side effects reported but poorly studied in humans; schisandra can inhibit CYP3A4 and CYP1A2 and long-term use can induce CYP3A4; it raises tacrolimus levels and inhibits P-glycoprotein.
Memorial Sloan Kettering Cancer Center, About Herbs: Schisandra
Nanai (Goldes/Samagir) hunters used schisandra berries and seeds as a tonic against thirst, hunger and exhaustion and to improve night vision; Russian interest arose from Komarov (1895) and Arsenyev (1903-1907); Soviet WWII military journals published the first tonic studies; Lazarev coined adaptogen in the 1950s and Brekhman and Dardimov formalized it in the late 1960s.
A fixed combination of Rhodiola, Schisandra and Eleutherococcus (ADAPT-232/Chisan) improved attention on the d2 Test in a pilot RCT in fatigued healthy women two hours after a single dose, illustrating that key human adaptogen data come from combination formulas rather than schisandra alone.
Panossian et al., Effects of Adaptogens on the Central Nervous System (Pharmaceuticals), PMC
Schisandra chinensis contains 86 identified lignans including schisandrol A/B, schisandrin A/B/C, which drive hepatoprotective, antioxidant and anti-inflammatory activity via mechanisms including Nrf2 activation; schisandrin chemistry underlies the liver drugs bifendate and bicyclol.
Schisandra sphenanthera lignans schisantherin A and schisandrin A inhibit CYP3A enzymes and increase tacrolimus exposure; a 14-day course raised tacrolimus bioavailability about 2.1-fold, and in CYP3A5 expressers schisandra cut the required tacrolimus dose by about 40 percent, requiring caution with narrow-window drugs.
PBPK modeling shows schisandra lignans (schisantherin A, schisandrin A, schizandrol A/B) interact with tacrolimus through CYP3A4/5, with the magnitude of interaction modulated by CYP3A5 genotype, reinforcing the clinical drug-interaction concern.
Li Shizhen's Bencao Gangmu recorded schisandra for liver-deficiency syndromes, and Schisandra-derived pharmaceutical agents bifendate (DDB) and bicyclol are used clinically for liver conditions in China.
The studies that matter
TCM classical inclusionShennong Bencao Jing (~200 CE)
Schisandra appears in the foundational Chinese materia medica as an upper-class ("superior") herb for longevity and tonification. Foundational classical evidence base from one of the oldest medical texts.
Soviet Brekhman performance research1960s-70s
Israel Brekhman's Soviet adaptogen research program included substantial Schisandra studies on physical performance, mental endurance, and aviation/cosmonaut applications. Substantial Russian-language evidence base; methodologically variable by modern Western standards but practically influential.
Hepatitis adjunctive clinical use1970s-90s
Chinese clinical research on Schisandra and isolated schisandrin compounds (particularly schisandrin B as Bicyclol/Biphenyl Dimethyl Dicarboxylate, marketed in China) in chronic hepatitis. Substantial Chinese-language clinical inheritance.
Hancke endurance trialPhytomedicine 1996
Chilean RCT in athletes: 90 days Schisandra extract improved physical performance and oxidative stress markers versus placebo. Foundational modern Western athletic performance evidence.
Lebedev hepatic protectionEksp Klin Farmakol 2001
Russian clinical trial: Schisandra extract in patients with chronic hepatic conditions showed improvements in liver function tests (ALT, AST, GGT) versus standard care. Modern evidence for hepatic protection use case.
Panossian Schisandra adaptogen reviewPhytomedicine 2008
Alexander Panossian comprehensive review of Schisandra pharmacology within the adaptogen framework. Established the integrated mechanistic and clinical framework. Industry collaboration disclosed.
Park hepatic toxicity protection trialJ Ethnopharmacol 2009
Korean RCT: Schisandra extract reduced ALT and AST elevations in patients with elevated liver enzymes. Established the clinical-grade modern hepatic evidence.
Aslanyan mental performance trialPhytomedicine 2010
Russian trial: ADAPT-232 (Schisandra + Eleutherococcus + Rhodiola combination) improved attention, speed, and accuracy in cognitive tasks under stress conditions versus placebo. Established the cognitive performance evidence in adaptogen combinations.
Park subclinical liver damage trialChin J Integr Med 2014
Korean RCT in subjects with subclinical liver damage: 12 weeks Schisandra extract reduced liver enzyme elevations and improved quality of life markers versus placebo. Modern hepatic evidence at modest effect sizes.
Szopa comprehensive reviewPlant Cell Tiss Org Cult 2017
Polish comprehensive review of Schisandra chemistry, pharmacology, and clinical evidence. Authoritative modern reference establishing the integrated framework across hepatic, performance, and adaptogenic applications.